How many EYP-1901 clinical trials are there?

8 EYP-1901 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 4 are marked completed.

Are EYP-1901 clinical trials recruiting in 2026?

Yes — 2 EYP-1901 trials are actively recruiting in 2026, with 97 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.

What conditions is EYP-1901 being studied for?

EYP-1901 is being studied for Diabetic Macular Edema, Wet Age Related Macular Degeneration, Diabetic Macular Edema (DME), DME, wAMD and 2 more. The trials are grouped by indication on this page.

What phase is EYP-1901 in?

EYP-1901 clinical trials span 4 Phase 3, 3 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors EYP-1901 clinical trials?

The lead sponsor across the most EYP-1901 trials is EyePoint Pharmaceuticals, Inc.. Each trial row links to the full study detail page including sponsor information.

EYP-1901 Clinical Trials (2026): 8 Studies for Diabetic Macular Edema & Wet Age Related Macular Degeneration

Creator: Hipa.ai Research
Published: 2026-04-21T18:15:49.121Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

8 EYP-1901 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Diabetic Macular Edema & Wet Age Related Macular Degeneration) and 1,562 total planned enrollment. 4 Phase 3 EYP-1901 trials and 3 Phase 2 are listed. 2 EYP-1901 clinical trials are actively recruiting at 97 U.S. sites across 29 states. Most recent activity: NCT07449936 (Oct 2028).

Where to Participate: All EYP-1901 Trial Sites in the U.S. (97 sites across 29 states)

Every actively recruiting EYP-1901trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AZ	Associated Retina Consultans	Gilbert85297	NCT07449923	Map
AZ	Associated Retina Consultants - Phoenix	Phoenix85020	NCT07449923	Map
AZ	Phoenix Retina Clinical Trials, LLC - North Phoenix	Phoenix85050	NCT07449923	Map
AZ	Retina Macula Institute of Arizona	Scottsdale85255	NCT07449923	Map
CA	California Retina Consultants	Bakersfield93309	NCT07449936	Map
CA	Retina Vitreous Associates Medical Group	Beverly Hills90211	NCT07449923	Map
CA	The Retina Partners	Encino91436	NCT07449936	Map
CA	Retina Consultants of Orange County	Fullerton92835	NCT07449923	Map
CA	Global Research Management, Inc.	Glendale91204	NCT07449936	Map
CA	South Coast Retina Center	Long Beach90807	NCT07449923	Map
CA	Retinal Consultants Medical Group - Modesto	Modesto95356	NCT07449923	Map
CA	Northern California Retina Vitreous Associates Medical Group INC.	Mountain View94040	NCT07449936	Map
CA	Kaiser Permanente	Oakland94611	NCT07449923	Map
CA	Retina Consultants of San Diego	Poway92064	NCT07449936	Map
CA	California Eye Specialists Medical Group, Inc.	Redlands92373	NCT07449936	Map
CA	Retina Consultants of Southern California	Redlands92374	NCT07449923	Map
CA	Retinal Consultants Medical Group	Sacramento95841	NCT07449936	Map
CA	Retinal Consultants Medical Group - Parkcenter Drive	Sacramento95825	NCT07449936	Map
CA	Bay Area Retina Associates	Walnut Creek94598	NCT07449923	Map
CO	Retina Specialists of Colorado - Arvada	Arvada80002	NCT07449923	Map
CO	Retina Consultants of Southern Colorado	Colorado Springs80909	NCT07449936	Map
CO	Colorado Retina Associates	Lakewood80228	NCT07449936	Map
CT	Connecticut Eye Consultants, P.C.	Danbury06810	NCT07449923	Map
CT	Coastal Eye Surgeons, LLC	Greenwich06830	NCT07449923	Map
CT	Retina Group of New England, PC	Waterford06385	NCT07449923	Map
FL	Advance Medical Research Group, Inc	Deerfield Beach33064	NCT07449936	Map
FL	Retina Group of Florida - Fort Lauderdale	Fort Lauderdale33308	NCT07449923	Map
FL	Retina Specialty Institute	Pensacola32503	NCT07449923	Map
FL	Eye Associates of Pinellas	Pinellas Park33782	NCT07449936	Map
FL	Fort Lauderdale Eye Institute	Plantation33324	NCT07449923	Map
FL	MedEye Associates	South Miami33143	NCT07449923	Map
FL	Retina Vitreous Associates of Florida - Saint Petersburg	St. Petersburg33711	NCT07449923	Map
FL	Retina Vitreous Associates of Florida - Saint Petersburg	St. Petersburg33711	NCT07449936	Map
FL	Southern Vitreoretinal Associates	Tallahassee32308	NCT07449936	Map
FL	Retina Vitreous Associates of Florida	Tampa33617	NCT07449923	Map
FL	Retina Specialists of Tampa	Wesley Chapel33544	NCT07449936	Map
GA	Georgia Retina	Marietta30060	NCT07449936	Map
HI	Retina Consultants of Hawaii	‘Aiea96701	NCT07449936	Map
IL	Retina Associates	Elmhurst60126	NCT07449923	Map
IL	University Retina and Macula Associates	Lemont60439	NCT07449923	Map
IL	Illinois Retina Associates, S.C.	Oak Park60304	NCT07449923	Map
IL	Red River Research Partners	Plainfield60586	NCT07449936	Map
IN	Associated Vitreoretinal & Uveitis Consultants - Carmel	Carmel46032	NCT07449923	Map
IN	Midwest Eye Institute - Carmel	Carmel11220	NCT07449936	Map
KY	The Eye Care Institute	Louisville40206	NCT07449923	Map
LA	Haik Humble Eye Center	West Monroe71291	NCT07449936	Map
MD	Retina Group of Washington	Chevy Chase20815	NCT07449936	Map
MD	Mid Atlantic Retina Specialists - Hagerstown	Hagerstown21740	NCT07449923	Map
MD	Retina Specialists - Towson	Towson21204	NCT07449936	Map
MA	New England Retina Consultants	Springfield01107	NCT07449936	Map
MI	Retina Associates of Michigan	Grand Blanc48439	NCT07449936	Map
MI	Foundation for Vision Research	Grand Rapids49546	NCT07449936	Map
MO	The Retina Institute	St Louis63128	NCT07449923	Map
NV	Sierra Eye Associates	Reno89502	NCT07449936	Map
NJ	Retina Center of New Jersey	Bloomfield07003	NCT07449923	Map
NJ	NJRetina Care Center - Teaneck	Teaneck07666	NCT07449936	Map
NJ	NJ Retina - Toms River	Toms River08755	NCT07449936	Map
NM	Vision Research Center at Eye Associates of New Mexico	Albuquerque87109	NCT07449923	Map
NY	Retina Vitreous Surgeons of CNY, PC	Liverpool13088	NCT07449923	Map
NY	Retina Associates of Western New York	Rochester14620	NCT07449936	Map
NY	VRCNY/Long Island Vitreoretinal Consultants	Westbury11590	NCT07449936	Map
NC	Asheville Eye Associates - Regional Medical Park	Asheville28803	NCT07449936	Map
NC	Graystone Eye - Hickory Office	Hickory28602	NCT07449923	Map
NC	North Carolina Retina Associates	Wake Forest27587	NCT07449923	Map
NC	Cape Fear Retinal Associates, PC	Wilmington28401	NCT07449936	Map
NC	Piedmont Retina Specialists, P.A. - Winston-Salem Office	Winston-Salem27103	NCT07449936	Map
OK	Retina Vitreous Center, PLLC	Edmond73013	NCT07449923	Map
OK	Tulsa Retina Consultant	Tulsa74114	NCT07449936	Map
OR	Verum Research, LLC	Eugene97401	NCT07449923	Map
PA	Erie Retina Research	Erie16507	NCT07449936	Map
PA	Wills Eye Hospital	Philadelphia19107	NCT07449923	Map
SC	Charleston Neuroscience Institute - Beaufort	Beaufort29902	NCT07449936	Map
SC	Carolinas Centers for Sight, P.C. - Florence Campus	Florence29501	NCT07449923	Map
SC	Retina Consultants of Carolina P.A	Greenville29605	NCT07449936	Map
TN	Charles Retina Institute	Germantown38138	NCT07449923	Map
TN	Tennessee Retina	Nashville37203	NCT07449936	Map
TX	Retina Research Institute of Texas Integrated Clinical Research	Abilene79606	NCT07449936	Map
TX	Austin Clinical Research LLC	Austin78750	NCT07449923	Map
TX	Retina and Vitreous of Texas	Bellaire77401	NCT07449923	Map
TX	Retina Consultants of Texas	Bellaire77401	NCT07449923	Map
TX	Texas Retina Associates	Dallas75231	NCT07449936	Map
TX	Mt. Olympus Medical Research	Houston77479	NCT07449936	Map
TX	Retina Consultants of Texas	Katy77494	NCT07449936	Map
TX	Texas Retina Associates	Plano75075	NCT07449936	Map
TX	Retina Associates of South Texas	San Antonio78240	NCT07449923	Map
TX	San Antonio Eye Center	San Antonio78215	NCT07449923	Map
TX	Retina Consultants of Texas	Schertz78154	NCT07449936	Map
TX	Retina Consultants of Texas	The Woodlands77384	NCT07449923	Map
TX	Tyler Retina Consultants	Tyler75703	NCT07449923	Map
TX	Strategic Clinical Research Group, LLC	Willow Park76087	NCT07449923	Map
UT	Retina Associates of Utah	Salt Lake City84107	NCT07449936	Map
UT	Salt Lake Retina	West Jordan84088	NCT07449936	Map
VA	The Retina Group of Washington	Fairfax22031	NCT07449923	Map
VA	Piedmont Eye Center	Lynchburg24502	NCT07449936	Map
VA	Virginia Retina Center	Warrenton20186	NCT07449936	Map
WI	Northeast Wisconsin Retina Associates	Appleton54914	NCT07449936	Map
WI	Eye Clinic of Wisconsin	Wausau54403	NCT07449923	Map

EYP-1901 clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	Total
P1			1	1
P2			3	3
P3	2	2		4

Recruiting EYP-1901 clinical trials (2)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07449936	DMECOMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME	P3	Diabetic Macular Edema	240	Feb 2026
NCT07449923	DMECAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME	P3	Diabetic Macular Edema	240	Feb 2026

EYP-1901 clinical trials by indication

Diabetic Macular Edema (3)

NCT	Acronym	Phase	Status	Title
NCT07449936	DME	P3	recruiting	COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923	DME	P3	recruiting	CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT06099184	VERONA	P2	completed	Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Wet Age Related Macular Degeneration (2)

NCT	Acronym	Phase	Status	Title
NCT06683742	wAMD	P3	active not recruiting	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06668064	wAMD	P3	active not recruiting	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Wet Age-related Macular Degeneration (2)

NCT	Acronym	Phase	Status	Title
NCT05381948	DAVIO2	P2	completed	Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
NCT04747197	—	P1	completed	First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Nonproliferative Diabetic Retinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT05383209	NPDR	P2	completed	Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

EYP-1901 pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
DME	NCT07449936	P3	recruiting	Diabetic Macular Edema	240	—
DME	NCT07449923	P3	recruiting	Diabetic Macular Edema	240	—
wAMD	NCT06683742	P3	active not recruiting	Wet Age Related Macular Degeneration	400	—
wAMD	NCT06668064	P3	active not recruiting	Wet Age Related Macular Degeneration	400	—
VERONA	NCT06099184	P2	completed	Diabetic Macular Edema	27	—
NPDR	NCT05383209	P2	completed	Nonproliferative Diabetic Retinopathy	77	—
DAVIO2	NCT05381948	P2	completed	Wet Age-related Macular Degeneration	161	—

All EYP-1901 trials (8)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07449936	DME	COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME	P3	recruiting	240	EyePoint Pharmaceuticals, Inc.	Feb 2026
NCT07449923	DME	CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME	P3	recruiting	240	EyePoint Pharmaceuticals, Inc.	Feb 2026
NCT06683742	wAMD	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56	P3	active not recruiting	400	EyePoint Pharmaceuticals, Inc.	Nov 2024
NCT06668064	wAMD	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56	P3	active not recruiting	400	EyePoint Pharmaceuticals, Inc.	Oct 2024
NCT06099184	VERONA	Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)	P2	completed	27	EyePoint Pharmaceuticals, Inc.	Jan 2024
NCT05383209	NPDR	Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)	P2	completed	77	EyePoint Pharmaceuticals, Inc.	Sep 2022
NCT05381948	DAVIO2	Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)	P2	completed	161	EyePoint Pharmaceuticals, Inc.	Jun 2022
NCT04747197		First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)	P1	completed	17	EyePoint Pharmaceuticals, Inc.	Jan 2021

EYP-1901 clinical trials: frequently asked questions

How many EYP-1901 clinical trials are there?: 8 EYP-1901 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 4 are marked completed.
Are EYP-1901 clinical trials recruiting in 2026?: Yes — 2 EYP-1901 trials are actively recruiting in 2026, with 97 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.
What conditions is EYP-1901 being studied for?: EYP-1901 is being studied for Diabetic Macular Edema, Wet Age Related Macular Degeneration, Diabetic Macular Edema (DME), DME, wAMD and 2 more. The trials are grouped by indication on this page.
What phase is EYP-1901 in?: EYP-1901 clinical trials span 4 Phase 3, 3 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors EYP-1901 clinical trials?: The lead sponsor across the most EYP-1901 trials is EyePoint Pharmaceuticals, Inc.. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming EYP-1901as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

EYP-1901 overview